Severe respiratory failure in the course of coronavirus disease 2019 treated with extracorporeal membrane oxygenation by Suwalski, Piotr et al.
S H O R T  C O M M U N I C A T I O N  ECMO for severe respiratory failure in COVID‑19 913
for severe respiratory insufficiency in the course 
of COVID‑19 and compare it with other cases de‑
scribed in the literature.
Methods Search strategy A systematic search 
for articles on the use of ECMO in patients with 
COVID‑19 was performed in the PubMed da‑
tabase on April 19, 2020 (Supplementary ma‑
terial). Only studies that reported the number 
of deaths were included. The identified studies 
were additionally analyzed by citation tracking 
to look for further eligible articles.
Statistical analysis Categorical variables were 
presented as frequency and percentages. Pa‑
tient informed consent to participate was not 
required for this study.
Results and discussion A 36‑year ‑old Cauca‑
sian man was admitted to the Department of In‑
ternal Medicine, Nephrology and Transplanta‑
tion Medicine because of fever, dyspnea, malaise, 
nonproductive cough that started 6 days earli‑
er, and 1‑day diarrhea. He reported close contact 
with a person who later tested positive for se‑
vere acute respiratory syndrome coronavirus 2 
(SARS ‑CoV‑2) that occurred 12 days before pre‑
sentation. Due to high fever, he was taking over 
the counter drugs including metamizole, acet‑
aminophen, and ibuprofen.
The patient was a professional driver and 
a bodybuilder, but he denied using anabolic 
Introduction The coronavirus disease 2019 
(COVID‑19) pandemic is a global threat. In most 
cases, patients develop mild symptoms and re‑
cover completely. Mortality due to COVID‑19 
is estimated to range between 0.99% and 3.4%, 
and significantly higher rates are observed in 
older age groups. It increases from 0.32% in in‑
dividuals younger than 60 years of age to 6.4% 
in those aged 60 years or older, and up to 13.4% 
in those aged 80 years or older. Other risk fac‑
tors include hypertension, diabetes, chronic 
obstructive pulmonary disease, cardiovascu‑
lar disease, and cerebrovascular disease.1 Death 
is usually caused by severe respiratory insuffi‑
ciency. While over 95% of people in Europe who 
died of COVID‑19 were over 60 years old, some 
young people suffer from the devastating ef‑
fects of the disease.
At present, the role of extracorporeal mem‑
brane oxygenation (ECMO) in the management 
of COVID‑19‑related severe respiratory failure 
remains unclear. The World Health Organiza‑
tion interim guidance recommends the follow‑
ing approach in “adult and pediatric patients 
with ARDS that fail lung protective ventilation 
strategy”: “In settings with access to expertise in 
extracorporeal membrane oxygenation (ECMO), 
consider referral of patients with refractory hy‑
poxemia despite lung protective ventilation.”2
Reports on the use of ECMO in COVID‑19 
are scarce. In this study, we report the case of 
a 36‑year ‑old man who was treated with ECMO 
Correspondence to: 
Prof. Andrzej Rydzewski, MD, PhD, 
Department of Internal Medicine, 
Nephrology and Transplantation 
Medicine, Centre of Postgraduate 
Medical Education, Central 
Clinical Hospital of the Ministry 










* PS and AR contributed equally 
to this work.
S H O R T  C O M M U N I C A T I O N
Severe respiratory failure in the course 
of coronavirus disease 2019 treated with 
extracorporeal membrane oxygenation
Piotr Suwalski1*, Andrzej Rydzewski2*, Rafał Wójtowicz3, Dominik Drobiński4, Jerzy Walecki5,7, Waldemar Wierzba6,7
1 Clinical Department of Cardiac Surgery, Centre of Postgraduate Medical Education, Warsaw, Poland
2  Department of Internal Medicine, Nephrology and Transplantation Medicine, Centre of Postgraduate Medical Education, Warsaw, Poland
3 Department of Anesthesiology and Intensive Care, Central Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland
4 Department of Cardiac Surgery, Centre for Extracorporeal Therapies, Central Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland
5 Department of Radiology, Centre of Postgraduate Medical Education, Warsaw, Poland
6  University of Humanities and Economics in Łódź, Satellite Campus in Warsaw, Warsaw, Poland
7 Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland
KARDIOLOGIA POLSKA 2020; 78 (9)914
hospitalization (oxygen saturation with oxygen 
delivered by a mask was 88%) and he was trans‑
ferred to the intensive care unit in our hospital. 
Meropenem, azithromycin, vancomycin, and 
lopinavir / ritonavir were added, and levofloxa‑
cin was discontinued. In the intensive care unit, 
the patient was intubated and received mechan‑
ical ventilation in the pressure ‑synchronized in‑
termittent mandatory mode. Alveolar recruit‑
ment maneuvers and intermittent prone posi‑
tioning were also used. Chest computed tomog‑
raphy on hospitalization day 5 demonstrated 
massive bilateral consolidations with periph‑
eral areas of ground ‑glass opacities, the crazy 
paving sign (particularly in the subpleural area), 
and bilateral pleural effusion (Supplementary 
material, Figure S2).
Due to further respiratory deterioration and 
worsening condition, a decision was made to 
put the patient on ECMO on hospitalization 
day 8. Veno ‑venous ECMO was instituted per‑
cutaneously following bedside ultrasound ex‑
amination of femoral vessels. A 23F drainage 
cannula was inserted through the right femoral 
vein and a 21F return cannula through the right 
jugular vein. These were subsequently connect‑
ed with tubes to the console (Cardiohelp Sys‑
tem, Getinge, Germany). Protective mechani‑
cal ventilator settings were used as the pressure 
control mode with peak pressure decreased to 
20 cm H2O, a fraction of inspired oxygen of 0.6, 
a positive end ‑expiratory pressure of 10 cm H2O, 
and an inspiratory ‑to ‑respiratory ratio of 2:1. 
Lung compliance in this case was critically low. 
steroids. He was a single, smoked 1 pack of cig‑
arettes a day, and drunk moderately. Apart from 
that, he had a history of allergy to penicillin.
On physical examination, his body tempera‑
ture was 39.6 °C; blood pressure, 140/87 mm Hg; 
pulse, 110 bpm; respiratory rate, 25 breaths per 
minute; and oxygen saturation, 98% on am‑
bient air. His Modified Early Warning Score 
was 3. Fine crackles were heard over the entire 
chest. The physical examination was otherwise 
unremarkable.
The patient’s laboratory parameters are pre‑
sented in Supplementary material, Table S1. No‑
tably, he had lymphocytopenia, high levels of lac‑
tate dehydrogenase, C ‑reactive protein, and pro‑
calcitonin, and tested positive for SARS ‑CoV‑2 
by reverse transcriptase–polymerase chain re‑
action. He also tested positive for hepatitis C 
(he was unaware of his hepatitis C virus status).
The first chest X ‑ray performed on admission 
showed massive bilateral pulmonary consoli‑
dations in the peripheral and lower areas and 
no pleural effusion (Supplementary material, 
Figure S1).
On hospitalization day 1, his dyspnea in‑
creased with oxygen saturation decreasing to 
90% on ambient air. He was treated with ox‑
ygen therapy delivered by a mask, levofloxa‑
cin, hydroxychloroquine (hydroxychloroquine 
was part of a standard hospital protocol based 
on the recommendations of the Polish Society 
of Epidemiology and Infectious Diseases), and 
paracetamol. Despite treatment, the patient’s 
condition deteriorated on the second day of 
TABLE 1 Studies reporting on extracorporeal membrane oxygenation use in patients with acute respiratory 
distress syndrome due to coronavirus disease 2019
Study ECMO, n ECMO survivors, n (%) Remarks
Bemtgen et al5 1 1 (100) Percutaneous ventricular assist device implantation
Hartman et al6 1 1 (100) –
Li et al7 8 3 (37.5) 1 patient still on ECMO
Ruan et al8 7 0 –
Tavazzi et al9 1 1 (100) Acute cardiac injury due to presence of the virus in 
myocardium
The patient survived ECMO but later died of sepsis
Wu et al10 1 0 –
Yang et al11 6 1 (16.7) The survivor still on ECMO at the end of the study
Zeng et al12 12 3 (25) 5 patients died
4 patients were still alive on ECMO, so the survival rate 
may be higher.
Zhan et al13 1 1 (100) –
Zhang et al14 10 2 (20) 2 patients were discharged, 3 died, and 5 were still on 
ECMO at the end of the study.
Zhou et al15 3 0 –
Present study 1 0 –
Abbreviations: ECMO, extracorporeal membrane oxygenation
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Despite the use of various ventilation modes, 
the respiratory volume did not exceed 100 ml. 
Oxygen saturation was monitored continuously. 
Packed red blood cells and fresh frozen plasma 
were transfused when needed. Kidney function 
remained normal during the course of the dis‑
ease, and small, left ‑sided peumothorax oc‑
curred on hospitalization day 5. Unfortunately, 
the disease deteriorated and the patient died of 
severe pneumonia, septic shock, and respirato‑
ry failure on hospitalization day 12.
The idea behind the use of veno ‑venous ECMO 
in patients suffering from acute respiratory dis‑
tress syndrome (ARDS) and refractory hypox‑
emia is that it promotes lung recovery by en‑
abling protective ventilation techniques and, 
thus, saving the lungs from injury related to 
mechanical ventilation.
The ECMO procedure may induce lymphocyte 
depletion, which is common in COVID‑19 and 
portends poor prognosis. However, we did not 
observe worsening lymphopenia after ECMO in‑
stitution in our patient. We had also been won‑
dering whether hepatitis C and possible ana‑
bolic steroid use might have been a factor pre‑
disposing to a severe course of the disease, al‑
though liver disease was not suggested to be 
a risk factor before.1
By PubMed search, we identified 11 papers 
describing a total of 51 patients.5-15 These data 
presented in TABLE 1 (including our case) suggest 
that the mortality rate in adult patients with 
COVID‑19 on ECMO is about 75%. This value is 
similar to that reported for COVID‑19 patients 
treated with ECMO,3 as well as in an observation‑
al, retrospective study of patients receiving ECMO 
and suffering from severe infections.4 Whereas 
total in ‑hospital mortality reported in the lat‑
ter study was 72%, the survival rate was much 
higher for community ‑acquired infections and 
for patients who were treated with ECMO with‑
in the first 4 days of hospitalization, which may 
suggest a similar early approach in COVID‑19.
In this short communication, we described 
a case of a young man with severe COVID‑19 
who died despite treatment with ECMO. We also 
reviewed studies reporting on ECMO use in pa‑
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